Evidence map›Paper›PMID 40191010›Full record

ArticleGastroenterology & hepatology2024

Remote Monitoring for Patients With Inflammatory Bowel Disease: Current Status and the Future of the Field.

Michelle D Dong, Jessica K Salwen-Deremer, Corey A Siegel

Abstract read
In one paragraph

Article in Gastroenterology & hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michelle D DongGeisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Jessica K Salwen-DeremerGeisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Corey A SiegelGeisel School of Medicine at Dartmouth, Hanover, New Hampshire.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a direct result of the COVID-19 pandemic, many advances in telehealth have been made that save time and reduce travel costs for patients. Telehealth, specifically video visits, was especially embraced by patients with inflammatory bowel disease (IBD). However, remote clinic visits are only one part of the equation for remote IBD care. Patients with Crohn's disease or ulcerative colitis have a significant testing burden, and many strides still need to be made to improve all aspects of their care, including remote monitoring (testing at home) of biochemical markers (eg, C-reactive protein and fecal calprotectin) and drug concentrations. Remote monitoring has the potential to decrease the burden of chronic disease on patients through improved ease of access, both when patients are feeling well and when they are having an exacerbation of symptoms. Numerous technologies are available in other countries, are used in other disease states, or are in the animal or early human testing phases. These innovations in home testing have the potential to improve testing adherence, disease control, and monitoring of IBD for all patients, and will have a particularly significant effect on those living in rural communities. This article reviews the current modalities for remote monitoring of patients with IBD as well as the methods in development to make monitoring of IBD easier for patients.

Indexed as

Crohn’s diseaseinflammatory bowel diseasemonitoringremoteruralulcerative colitis

Identifiers

PMID40191010
PMCPMC11966233

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.